

Nonreplicating adenoviral vectors: Improving tropism and delivery of cancer gene therapy


Nayara Gusmão Tessarollo

Federal University of Viçosa | Brazil



Abstract

Melanoma is the most aggressive type of skin cancer and has a high lethality. The treatment of cancer has progressed greatly with the advent of immunotherapy and gene therapy, including the use of nonreplicating adenoviral vectors to deliver genes with antitumor activity for cancer gene therapy. Adenoviruses were the first DNA viruses to go into therapeutic development, mainly due to well-known biological features: stability in vivo, ease of manufacture, and efficient gene delivery to dividing and nondividing cells. Our group has shown that the combined gene transfer of p19Arf and IFN β delivery by nonreplicating adenovirus type 5 is an efficient means to induce both cell death and immune response. In addition to promoting emission of critical markers of immunogenic cell death, combined p19Arf+IFN β promotes a Th1 immune response with participation of neutrophils, natural killer cells, and both CD4 + and CD8 + T lymphocytes. While our approach acts as immunotherapy, we wish to further strengthen the immune response by directing cytolytic T cell activity towards tumor-specific antigens. In this context, we evaluated whether tumor neoantigens would enhance the immune response induced by the prophylactic vaccination of immunocompetent mice. For this, B16 (mouse melanoma) cells were treated ex vivo with the adenoviral vectors encoding p19Arf and IFN β and applied (s.c.) as a vaccine with or without the presence of the neoantigens. Later, a rechallenge with naïve B16 cells (s.c. in the opposite flank) was performed and the animals were observed for progression of the secondary tumor. Indeed, tumor progression was diminished when the vaccine included the neoantigens. Currently, we are evaluating the specific response of T cells to the neoantigens and we are exploring alternative methods for introducing the neoantigens in the treatment approach.



Biography

Nayara is graduated in Biochemistry at Federal University of Viçosa (Brazil) in 2010 and she got her master's degree in Health Science (Concentration Area: Cell and Molecular Biology) at René Rachou Research Center- FIOCRUZ (Brazil) in 2013. She got her Ph.D. in Biotechnology by Federal University of Espírito Santo (Brazil) in 2017 with internship period at Johns Hopkins University (Baltimore, MD, United States) under the supervision of Dr. Ie-Ming Shih at the Molecular Genetics Laboratory of Female Reproductive Cancer in June/2014 - May/2015. She is a Postdoctoral Fellow in the Center for Translational Investigation in Oncology at ICESP, the Cancer Institute of the State of São Paulo /Brazil.

Publications

1. Metformin and mTOR Inhibitors: Allies against Ovarian and Breast Cancers
2. Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy
3. Enhancement of cisplatin activity against triple negative breast cancer cells by atorvastatin
4. The hybrid AAVP tool gets an upgrade
5. Advanced biomaterials for cancer immunotherapy

[4th World Congress on Vaccines & Immunization](#) | London, UK | June 09, 2021

Citation: Nayara Gusmão Tessarollo, Nonreplicating adenoviral vectors: Improving tropism and delivery of cancer gene therapy, Vaccines 2021, 4th World Congress on Vaccines & Immunization, London, UK, June 09, 2021